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Abstract 
Diffusion-weighted magnetic resonance imaging (MRI) provides unparalleled information and 
measurements of lung structure and function without the burden of ionizing radiation.  In 
particular, diffusion-weighted MRI provides estimates of airspace enlargement, which is a 
hallmark characteristic of emphysema.  MRI provides a way to measure in vivo mean-linear-
intercept (Lm) and this is a promising measurement for clinical evaluation of disease 
progression in patients with Alpha-1 Antitrypsin Deficiency (AATD) in which airspace 
enlargement begins early in life.  As such, our objective was to evaluate MRI measurements 
of airspace enlargement in AATD patients and compare these measurements to ex-smokers 
with chronic obstructive pulmonary disease (COPD) and healthy never-smokers.  We 
compared these measurements with standard clinical measurements provided by spirometry, 
plethysmography and computed tomography; we also demonstrated that MRI detected 
differences in disease severity in patients with clinically similar measurements.    
(135/150 words) 
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1 INTRODUCTION 
“Can one hear the shape of a drum?” - Mark Kac.1  This simple question builds the 
foundation for this research.  Can you listen to an MRI signal from the lung parenchyma 
and from that determine its shape and form? This introduction provides the required 
information as a prelude to the remaining chapters which explore this question across a 
range of lung disease. 
 Motivation and Rationale 
Chronic obstructive pulmonary disease (COPD) is a leading cause of death and 
hospitalizations worldwide.2  It affects millions of people and has an incredible economic 
burden on the healthcare system in Canada.3  The hallmark features of COPD include 
thickening of the bronchial walls, excessive mucus production and partial or complete 
destruction of the alveolar ducts and sacs.4  This combination of factors leads to a decrease 
in pulmonary function and overall quality of life.  Individuals with a diagnosis of Alpha-1 
Antitrypsin Deficiency (AATD) lack a protein required for regulation of neutrophil elastase 
and as a result can rapidly develop a phenotype of COPD called emphysema.5  
Unfortunately, there is no cure for AATD and current treatment is expensive,6 and has 
controversial efficacy with no improvements in exercise capacity or quality of life for the 
patient.7  Emphysema is characterized by parenchymal destruction which results in overall 
airspace enlargement.  This enlargement can be characterized by lung morphometry, the 
study of lung form.  This can be used to quantify disease severity and progression 
regionally throughout the lung.  The American Thoracic Society (ATS) and European 
Respiratory Society (ERS) joint task force consider quantification of lung structure to be 
the gold standard in evaluating clinical interventions, severity of disease and response to 
treatment.8   
In the clinic, measurements of lung structure and function are made using a wide range of 
tools, from simple airflow measurements to complex three dimensional computed 
tomography (CT).  Many of these tools will be outlined in further detail later in this chapter.  
Airflow measurements (spirometry) taken at the mouth can be used to quantify lung 
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function and airflow obstruction. Spirometry is the gold standard for diagnosis of chronic 
obstructive pulmonary disease.  It is also possible to measure lung volumes which can give 
the volume of gas remaining in the lungs after full exhalation.  The volume remaining at 
the end of exhalation (RV) as a ratio of total lung capacity (TLC) is a measurement of gas 
trapping.  Diffusion tests can give an estimate of the ability for O2 to diffuse across the 
alveolar-capillary membrane which is a quantity that is reduced in diseases such as 
emphysema.  Measurements of lung structure and form can be performed using imaging 
techniques such as planar x-rays or by extending this to 3D x-ray CT.  These techniques 
allow measurements of lung volumes and tissue density to be made but to truly measure 
the structure and form of the lung and the lung parenchyma, novel morphometry techniques 
must be employed to obtain measurements such as the surface-to-volume ratio and mean 
cord length. 
Lung morphometry is not a new field.  However, until recently, it relied on histology to 
provide 2D cross sections with which the overall 3D structure of the lungs are estimated.9,10  
In this method, an excised lung or section of the lung is sliced into 2D cross sections and 
through point counting, intersection counting and transect counting an estimation of lung 
volume, surface area or mean cord length can be made.9  Unfortunately, this method relies 
on excised lung tissue thus limiting it to ex-vivo analysis. 
Unfortunately, there are limited methods that provide accurate measurements of airspace 
size in vivo.  Hyperpolarized noble-gas magnetic resonance imaging (MRI) provides an 
ionizing radiation free method of quantifying lung structure function in vivo.  To 
accomplish this, diffusion-weighted MRI is employed, which measures the self-diffusion 
of the noble-gas molecules within the confinement of the lung parenchyma.  Since the 
noble-gases used are biologically inert, this diffusion is related to the confining geometry, 
in this case that of the lung parenchyma.  There has been much work done in measuring 
this confinement in the form of an apparent diffusion coefficient (ADC).  Previous work in 
AATD measuring ADC,11-14 relied on the single diffusion-weighted approach and did not 
extend to multiple diffusion-weights which can provide a more sensitive measurement of 
geometry.  Recent work however, looked at a population of AATD subjects using different 
multiple diffusion-weighted modelling approaches but did so only for a single centre 
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coronal slice and without comparison to standard clinical measurements or regional 
evaluation.15  
This thesis focuses on evaluation of alveolar destruction in COPD and AATD using 
multiple diffusion-weights, comparing these measurements to those used clinically such as 
spirometry and computed tomography as well as evaluating measurements of airspace 
enlargement regionally throughout the lung. 
This thesis chapter will provide prerequisite knowledge to understand the original research 
presented in Chapter 2.   
 Lung Structure and Function 
The primary function of the lungs is gas exchange.  The lungs consist of branching 
generations (Figure 1-1) of bronchioles which ultimately end in the alveoli, where the 
majority of gas exchange occurs.  The lungs can be divided into two sections, the 
conducting zone and the respiratory zone. 
1.2.1 Conducting Zone 
Beginning at the nose, the conducting zone is the first portion of the respiratory tract.  This 
portion of the airways consists of those with the largest diameter with the main purpose of 
filtration, warming and transportation of incoming air.  The conducting zone concludes at 
the terminal bronchioles.  In the respiratory tract, the conducting zone consists of 
generations 1 to 16.   
1.2.2 Respiratory Zone 
The respiratory zone, generations 17 until the alveoli is the site of gas exchange in the 
lungs.  This is the portion of the respiratory tract with the largest surface area which makes 
up the bulk of the lung parenchyma.  This region of the lung consists primarily of the 
alveolar ducts, sacs and the alveoli.  The alveoli are responsible for 90% of the gas 
exchange whereas the preceding respiratory bronchioles and alveolar ducts account for 
only 10%. 
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Figure 1-1: Conducting and Respiratory Zones 
Respiratory tract generations (Z) with both conducting and respiratory zones beginning at 
the trachea (Z = 0) and ending at the alveoli (Z = 23). Adapted from West, JB, Respiratory 
Physiology: The Essentials, Ninth Edition.16 
 
1.2.3 The Alveoli 
The alveoli comprise the bulk of the lung parenchyma as they line the walls of the airways 
in the respiratory zone.  Each alveolus is approximately 330 um in diameter16 and the 
average adult has 480 million alveoli.17  As a result of their small diameter and the vast 
number of alveoli, they have a surface area of roughly 70 m2.18  This is the hallmark feature 
of the efficient lung, as the total surface area influences its ability to receive deoxygenated 
blood and inversely supply the heart with oxygen during respiration.  Any disease which 
results in destruction to the alveoli will ultimately reduce the surface area available for gas 
exchange and in turn result in a reduction of pulmonary function and quality of life for the 
individual. 
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 Chronic Obstructive Pulmonary Disease 
Having classically been defined as consisting of two distinct, but intertwined, phenotypes 
COPD is a progressive disease leading to airflow limitations and reduced quality of life.  A 
patient with chronic bronchitis, often referred to as a “blue bloater”, can be visualized as a 
person with a larger stocky build and a history of a chronic cough.4  A patient with 
emphysema, often referred to as a “pink puffer”, will be someone with recent weight loss 
and abnormal physical weakness.4  The current diagnostic criteria for COPD are outlined 
by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.19  The 
GOLD severity grades are provided in Table 1-1 where FEV1 is an airflow measurement 
taken using a spirometer explained in more detail in Section 1.5.1. 
Table 1-1: GOLD Severity Grades 
Patient with FEV1/FVC < 70% 
GOLD I  Mild FEV1 ≥ 80%pred 
GOLD II Moderate 50% ≤ FEV1 < 80%pred 
GOLD III Severe 30% ≤ FEV1 < 50%pred 
GOLD IV  Very Severe FEV1 < 30%pred 
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity 
1.3.1 Chronic Bronchitis 
Chronic bronchitis is inflammation of the bronchial tubes, primarily in the mucus glands.4  
This inflammation results in an over-production of mucus by the goblet cells which are 
located on the epithelial lining of the respiratory tracts.20  The combination of mucus lining 
the bronchial tubes and the inflammation results in airflow limitations.  The primary cause 
of chronic bronchitis is cigarette smoking, but that is not the only cause.4,21 
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1.3.2 Emphysema 
Emphysema affects the airspace distal to the terminal bronchioles.  It is characterized by 
the destruction of the walls of the alveolar ducts, sacs, or both.4  It is a result of an imbalance 
of proteases due to either an increased production of proteases or reduced production of 
antiproteases.22  There are two main types of recognized emphysema (Figure 1-2): 
Centriacinar emphysema, where destruction is limited to the central lobule leaving the 
alveolar ducts and sacs unharmed and panacinar emphysema where destruction occurs 
across the entire lobule. 
 
Figure 1-2: Centriacinar and Panacinar Emphysema 
Normal respiratory bronchioles, respiratory bronchioles affected by centriacinar 
emphysema where the emphysema is confined the terminal and respiratory bronchioles 
(TB and RB).  This destruction is extended to the alveoli (A) in panacinar emphysema. 
Adapted from West, JB, Pulmonary Pathophysiology: The Essentials, 4th Edition.4 
The destruction of the lung parenchyma can be seen in Figure 1-3 showing micro-CT 
images of a healthy young subject, healthy elderly subject and an ex-smoker.  All three 
images have the same field of view (FOV) = 40mm. 
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Figure 1-3: Micro-CT Lung Images 
Micro-CT images showing a healthy young lung with tightly packed alveoli, a healthy old 
lung23 showing gradual enlargement of the lung parenchyma and an ex-smoker lung23 
showing emphysematous destruction of the lung parenchyma. (Healthy young lung 
courtesy of Dr. Vasilescu and Dr. Hogg (UBC)). Healthy Old Lung and Ex-Smoker Lung 
reproduced with permission (Appendix A). 
Emphysema is most frequently encountered in the proximal respiratory bronchioles in the 
upper lobes.24,25  This is referred to as centrilobular emphysema and is primarily associated 
with smoking related emphysema.  Emphysema can also be located distal to the respiratory 
bronchioles localized in the basal portion of the lung. This pattern of emphysema is referred 
to as panlobular emphysema and is characteristic of, but not limited to, AATD related 
emphysema.26 
 Alpha-1 Antitrypsin Deficiency 
1.4.1 Biology 
AATD was first described in 1963 by Laurell and Eriksson.27  AATD is an underdiagnosed 
genetic condition affecting up to 1 in 1500 people of European descent.6,28  It causes 
mutations in the SERPINA1 gene which contains instructions for producing a protein 
called alpha-1 antitrypsin.  This protein protects the body from neutrophil elastase, which 
is released from white blood cells in response to infection but will attack healthy tissue if 
not regulated.29,30   The normal allele of the SERPINA1 gene, M, results in normal levels 
of alpha-1 antitrypsin.  Two other variants the S and Z variants produce decreasing amounts 
of alpha-1 antitrypsin.31  There are over 100 different alleles worldwide.32 
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1.4.2 Liver Disease 
Approximately 15% of all alpha-1 antitrypsin deficiency sufferers will develop liver 
disease.33  As the alpha-1 antitrypsin is not secreted properly34 (as a result of protein mis-
folding) it accumulates in the liver and can cause liver cirrhosis, an accumulation of liver 
scar tissue.35 
1.4.3 Lung Disease 
AATD primarily manifests in the form of panlobular emphysema.  The imbalance of 
neutrophil elastase will result in destruction of connective tissue within the lungs and a 
breakdown of the alveoli leading to reduced surface area and in turn diminishing the lungs’ 
capacity for gas exchange.  Emphysema as a result of AATD predominately affects the 
basal portion (~64% of patients)36 of the lung due to the gravitational dependence of 
pulmonary blood flow.  This is not always the case and upper lobular emphysema can also 
occur as can other respiratory disorders such as bronchiectasis.37 
1.4.4 Augmentation Therapy 
At this time there is no cure for AATD and current treatment is geared solely towards 
symptomatic relief.32  Intravenous supplementation of exogenous alpha-1 antitrypsin has 
been shown to both slow the decline of the forced expiratory volume in 1 second (FEV1) 
in patients with AATD38,39  and slow the decline in lung tissue density as measured by x-
ray computed tomography.7  Augmentation therapy is a costly procedure and there are 
some debates on who would benefit the most from treatment.40  In addition, recent clinical 
trials have not shown significant changes in exercise capacity, patient perceived quality of 
life, exacerbations or hospitalizations as a result of treatment.7  To overcome this, there is 
preliminary work examining novel treatments for AATD emphysema including gene 
therapy41-44 and pluripotent stem cells.45,46  In order to accurately gauge the efficacy of 
these novel treatments, pulmonary imaging must be employed as it has previously played 
an important role in demonstrating treatment efficacy with respect to lung density changes.  
However, to truly measure airspace enlargement in vivo lung morphometry techniques, 
which can give measures of airspace enlargement and surface-to-volume ratios, are 
required.  These measurements must be sufficiently sensitive to detect small changes in 
 9 
 
early and mild disease as well as severe end stage emphysema.  If a sensitive measurement 
of disease and airspace enlargement were developed and applied to clinical efficacy 
evaluation of novel treatments it would be possible to perform smaller single-centre 
studies.  This would result in a drastic reduction in costs and ultimately aid in the 
development of novel treatments of AATD emphysema. 
 Clinical Measurements of Lung Disease 
1.5.1 Spirometry 
Worldwide, spirometry provides the gold standard measurement for the diagnosis and 
clinical evaluation of COPD.19  Spirometry tests by patients who are coached by a trained 
pulmonary technologist for which there are accepted guidelines on reproducibility and 
evaluation.47   Spirometry measurements are inexpensive and reproducible while requiring 
little specialized equipment or training; however, they rely solely on airflow measurements 
taken at the mouth and therefore provide a single global measurement representing lung 
function.47  This unfortunately fails to unmask the many faces of COPD and hides its 
underlying heterogeneity.48,49  The primary measurement of airflow limitation is the FEV1 
which is a measurement of the maximum amount of air exhaled during the first 1 second 
of a forced expiration.  Figure 1-4 shows a sample flow volume curve for a normal healthy 
individual (Figure 1-4A) and a flow volume curve for someone with an obstructive lung 
disease (Figure 1-4B).  The total volume of air exhaled during this breathing maneuver is 
the forced vital capacity (FVC). 
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Figure 1-4: Flow Volume Curve 
Sample flow volume curves for a healthy (A) patient and someone with obstructive lung 
disease (B). In obstructive lung disease, flow rates are slower resulting in a lower FEV1. 
1.5.2 Lung Volumes and Capacities 
In addition to FEV1 and FVC it is possible to measure patient lung volumes using a 
plethysmograph.  Briefly, a plethysmograph is a closed system in which the patient sits that 
is used to measure lung volumes, specifically the functional residual capacity (FRC), total 
lung capacity (TLC) and the residual volume (RV).  FRC is the volume of air in the lungs 
remaining at the end of a passive expiration during a normal breathing cycle and RV is the 
volume of air in the lungs remaining at the end of a full expiration.  To accomplish this 
Boyles law is implemented and using measured pressure differences one can derive the 
aforementioned lung volumes.50 
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Figure 1-5: Lung Volumes 
A volume time curve showing clinically relevant lung volumes.  Relevant lung volumes 
for this work are: Residual Volume (RV), the volume remaining after full expiration; 
Functional Residual Capacity (FRC), the volume remaining after passive expiration and 
Total Lung Capacity (TLC); the total lung volume after a full inspiration. 
The measurement of TLC and RV/TLC is important as it represents hyperinflation of the 
lungs which is a hallmark sign of COPD due to either the loss of the elastic property of the 
lung parenchyma or an obstruction in the passage of air. 
1.5.3 Diffusing Capacity of the Lung for Carbon Monoxide 
The diffusing capacity of the lung for carbon monoxide (DLCO) test measures the amount 
of oxygen passing from the alveolar sacs into the blood.  During the test the patient breathes 
in a test gas containing a small amount of tracer gas (CO) and holds their breath.51  CO is 
used due to its affinity to bind to hemoglobin, making the uptake of CO diffusion limited 
as opposed to perfusion limited.  This means that the amount of gas taken up is solely 
dependent on diffusion and not the amount of available blood flow.4  Upon a breath-hold 
of 10 seconds the patient exhales and the exhaled gas is tested to determine the amount of 
tracer gas that was absorbed during the duration of the breath hold.51  This test is especially 
important in patients with emphysema as the destruction of the alveolar sacs leads to a 
decreased capacity for gas exchange between the air sacs and blood.  A measurement of 
DLCO normalized to the alveolar volume (DLCO/VA) has been proposed as a more specific 
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measurement.52,53  Although simple and quick, this tests lacks reproducibility over time54 
and therefore may be unattractive in cases where longitudinal monitoring may be required.  
A low DLCO combined with an increase in TLC, RV/TLC is a classic sign of emphysema 
as observed by pulmonary function testing.55 
1.5.4 Six-Minute Walk Test 
Patient exercise capacity can be measured by performing the six-minute walk test (6MWT).  
In the 6MWT the patient walks at a self-set pace, resting as necessary, on a flat surface for 
six minutes.  The six minute walk test does not provide specific information of the limiting 
exercise factor but is reflective of the activities performed during day to day life.  Before 
and after performing the six minute walk test the patient answers two questions on 
perceived levels of exhaustion56 and has measurements of arterial oxygenation (SPO2) and 
heart rate taken.  All six minute walk tests performed for this thesis are to American 
Thoracic Society guidelines.57,58 
1.5.5 St. George’s Respiratory Questionnaire 
The St. George’s Respiratory Questionnaire (SGRQ)59 is designed to measure the overall 
impact that respiratory disease has on the quality of life as perceived by the patient.  There 
are two sections a symptoms section and an activities section which relate to the symptoms 
experienced and the burden of the disease.  The questionnaire is scored from 0 to 100 with 
higher scores indicating worse perceived quality of life and symptoms. 
 X-Ray Computed Tomography 
1.6.1 Theory 
At its most basic level, x-ray computed tomography (CT) is an extension of planar x-ray 
imaging to three dimensions using a rotating x-ray tube and detector combined with a 
motorized patient bed.60  The contrast in the image is related to the radiodensity of the 
scanned material where each value represents a Hounsfield unit (HU) corresponding to: 
 𝐻𝑈 = 1000 ∗
𝜇 − 𝜇𝑤𝑎𝑡𝑒𝑟
𝜇𝑤𝑎𝑡𝑒𝑟 − 𝜇𝑎𝑖𝑟
 (1-1) 
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With 𝜇 being the linear attenuation coefficient and 0 HU being defined as the radiodensity 
of distilled water at standard pressure and temperature. 
1.6.2 Pulmonary X-Ray Computed Tomography 
CT imaging of the lung can be used to visualize regions of low attenuation and quantify 
both gas trapping and emphysema.  Typical lung parenchyma attenuation values are 
between -910 and -500 HU.61  A CT scan performed at full expiration can be used to 
quantify regions of gas trapping which are regions where gas is not cleared through 
exhalation.  To do so the regions of the lung <-856 HU are examined.62  A full inspiration 
CT can be used to quantify regions of emphysema.  Using the attenuation <-950 HU as an 
emphysema threshold.63  This can be quantified using the relative area of the CT density 
histogram with values <-950 HU (RA950).  RA950 measurements correlate well with 
radiologist scores,64 histology65  and pulmonary function testing.66  Regions of the CT lung 
density histogram representing airspace enlargement are shown in Figure 1-6 for a healthy 
never-smoker and representative AATD subject.  Combining inspiration and expiration CT 
scans together, a regional map of gas trapping and emphysema can be made.67  This 
method, called parametric response mapping, co-registers the inspiratory and expiratory 
CT scans and generates a lung map showing regions of gas trapping and emphysema.  
These methods can provide regional information of emphysema and gas trapping 
throughout the lung.  In addition to quantifying regions of emphysema and gas trapping 
CT provides a measurement of lung density (g/L).68,69  Unfortunately, current spatial 
resolutions available with CT are not fine enough to visualize the smaller airways.  There 
are other quantification methods such as examining low attenuating clusters (LAC)70 where 
the cumulative size distribution of these low attenuating clusters (<-950 HU) are described 
by a power law relationship with the number of low attenuating clusters.  This in principle 
relates the size of these emphysematous lesions and the number of lesions using CT.  This 
can be graphically illustrated as low attenuating spheres where the size of the sphere is 
proportional to the cumulative lesion size. 
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Figure 1-6: CT Radiodensity and Histogram 
CT images with yellow masks corresponding to voxels <-950 HU and the corresponding 
whole lung CT radiodensity histogram for a healthy never-smoker and subject with 
AATD 
Since the development of micro-CT spatial resolutions approaching 4 µm may be 
obtained.71  Micro-CT as a method of visualizing and quantifying lung morphometry has 
been thoroughly demonstrated in mice,72 pigs73 and cadaveric human lung specimens,23,71 
including AATD donor lungs;74  however, the scan speed and radiation exposure required 
to execute a scan leaves the feasibility of micro-CT geared solely to ex-vivo imaging.75,76 
 Magnetic Resonance Imaging 
1.7.1 Theory 
Conventional 1H MRI of the body is possible due to the high concentration of 1H molecules 
comprising various biological tissues.  The gyromagnetic ratio (γ) of a nucleus will in part 
determine the MR signal.  The high γ of 1H (γ1H = 42.6 MHz T-1) combined with the natural 
abundance of 1H located inside biological tissue provides ample signal for imaging most 
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of the body.  Unfortunately, the lungs have incredibly low density (133g/L - 200g/L)77 and 
have millions of air tissue interfaces which result in magnetic field inhomogeneities within 
the lung parenchyma.  This makes clinically available 1H MRI unsuitable for quantitative 
evaluation of the lung or the diseases which affect it. 
1.7.2 Pulmonary Magnetic Resonance Imaging 
Conventional 1H MRI of the lungs is difficult due to the high concentration of air contained 
within the lungs, and consequently the low tissue density.77  This is made further 
complicated by the large number of air-tissue interfaces which affect magnetic field 
homogeneity within the lungs.  For these reasons, the lungs appear as dark voids (Figure 
1-7) providing little to no information on lung structure-function. 
 
Figure 1-7: 1H Thorax image for representative NS, COPD and AATD Subjects 
This limitation can be circumvented by using multinuclear MRI and as opposed to 
measuring 1H density, one measures the relative density of an inhaled hyperpolarized 
noble-gas.  Through spin-exchange optical pumping, noble-gases can be hyperpolarized 
and used for imaging of the lungs after inhalation.78  This is important because the MRI 
signal is proportional, to the following factors:79 
 
𝑆 ∝
1
2
𝑁|𝛾|ℏ𝜔0𝑃𝑁 
(1-2) 
Where S is the MRI signal, N is the number of spins, γ is the gyromagnetic ratio, ℏ is the 
reduced Plank constant, 𝜔0 is the Larmor frequency and PN is the nuclear polarization.  In 
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the case of 1H MRI the high N provides adequate signal for imaging purposes; however,  
in the case of hyperpolarized noble-gas imaging thermally polarized noble-gas to provides 
inadequate signal due to the small N and PN.  However, this can be overcome by raising 
the PN through external polarization of the noble-gas.  This technique allows visualization 
of gas dispersion within the lungs. 
1.7.2.1 1H Methods 
There are however methods utilizing traditional 1H imaging which provide information 
suitable for quantitative image analysis.  These methods are currently under investigation 
in research settings but may serve to provide translatable lung imaging.  Two methods are 
Fourier decomposition (FD) MRI80 and Ultrashort Echo Time (UTE) MRI.81  
1.7.2.1.1 Fourier Decomposition 
During a period of free breathing, multiple images are taken of a single slice through the 
lungs.  The images are then deformably registered82 to each other to account for cardiac 
motion and the varying lung volumes throughout the respiratory cycle.  The discrete 
Fourier transform is taken at each lung voxel and ventilation and perfusion maps can be 
obtained by observing the corresponding peak at either the respiratory rate (ventilation) or 
cardiac rate (perfusion).  Ventilation maps obtained from FD MRI have been shown to 
correlate with ventilation maps obtained from 3He.83   
1.7.2.1.2 Ultrashort Echo Time 
To overcome the difficulties in lung imaging a method using echo times (TE) of ~50us and 
3D radial k-space trajectories has been developed.  MRI is performed at four lung volumes: 
full expiration, FRC, FRC+1L and full inhalation.  Absolute signal intensity is normalized 
to the liver and dynamic proton maps (registered to FRC+1L) can be computed using the 
lung volumes.  The UTE signal has been shown to be related to lung volume suggesting a 
relationship to tissue density.84  It is also related to gas-trapping in asthmatics.85  
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1.7.2.2 Hyperpolarized Methods 
1.7.2.2.1 Spin Physics and Polarization 
By using spin-exchange optical pumping (SEOP) high levels of 3He or 129Xe polarization 
can be achieved.79  The SEOP system uses circularly polarized resonance light which is 
absorbed by rubidium housed within a glass cell.  Contained within the same glass cell is 
the noble-gas used in the spin-exchange, 3He in this case.  Angular momentum is 
transferred through binary collisions from the polarized rubidium to the 3He.  Over time as 
collisions increase, this causes an increase of the 3He nuclear polarization to several orders 
of magnitude larger than the thermal polarization obtained using magnetic fields.  A full 
theoretical description of SEOP of noble-gas nuclei can be found in a review by Walker 
and Happer 1997.86 
1.7.2.2.2 Static Ventilation MRI 
By imaging the spin density of the polarized noble-gas during a breath-hold, visualization 
of gas distribution throughout the lungs can be achieved.  These images are coined static 
ventilation (SV) images and as the name indicates they give a single static image of gas 
distribution.  This is shown in Figure 1-8, these are the same subjects and slices as Figure 
7.  This image, can be qualitatively analyzed by identifying regions of hypo-intense signal 
(signal voids) as well as regions of hyper-intense signal.  These regions can also be 
quantified using semi-automated segmentation methods,87 where the 1H and 3He images 
are co-registered using an affine transformation, to determine the ventilation defect percent 
(VDP) which is the volume of ventilation defects (signal voids) normalized to the thoracic 
cavity volume. 
 
𝑉𝐷𝑃 [%] =  
𝑉𝑒𝑛𝑡𝑖𝑙𝑎𝑡𝑖𝑜𝑛 𝑑𝑒𝑓𝑒𝑐𝑡 𝑣𝑜𝑙𝑢𝑚𝑒
𝑇ℎ𝑜𝑟𝑎𝑐𝑖𝑐 𝑐𝑎𝑣𝑖𝑡𝑦 𝑣𝑜𝑙𝑢𝑚𝑒
 𝑥 100% 
(1-3) 
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Figure 1-8: Static ventilation images for representative NS, COPD and AATD 
subjects 
3He static ventilation (cyan) overlaid on 1H thorax image for a representative subjects 
VDP has been shown to correlate with aging,88 ventilation homogeneity,89 and 
spirometry.90 VDP shows response to bronchodilation in asthmatics,91 as well as response 
to bronchoconstriction (methacholine).92  
1.7.2.2.3 Diffusion-weighted MRI 
Using a similar method to what is used to acquire SV images, and employing a diffusion-
weighted pulse sequence93 (Figure 1-9) diffusion-weighted images can be acquired. Due 
to the loss of the MR signal at high b-values, the highest b-values are acquired first to 
maximize the signal at those values.  The diffusion gradient is shown in blue for interleaves 
2-5.  These images allow visualization and quantification of the extent to which the noble-
gas molecules are able to diffuse within the confining space of the alveolus.94   
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Figure 1-9: Diffusion-weighted Pulse Sequence 
A multiple b-value fast gradient recalled echo (FGRE) pulse sequence.  Interleave 1 
acquires a non-diffusion-weighted static ventilation image and interleaves 2-5 acquire 
diffusion weighted images due to the diffusion gradient (in blue).  The size and strength of 
the diffusion gradient are varied to acquire multiple b-values. 
1.7.2.2.4 Apparent Diffusion Coefficient 
In a confined medium, such as an airway or alveolus, the root mean square displacement 
(<r2>) of a noble-gas molecule and its diffusion time (t) can be related to an apparent 
diffusion coefficient (ADC) giving a relative measure of confinement: 
 
𝐴𝐷𝐶 =  
< 𝑟2 >
2𝑡
 
(1-4) 
Diffusion-weighted MRI can extract this ADC through diffusion-weighted pulse sequences 
(Figure 1-9).  First, a non-diffusion-weighted (static ventilation) image is acquired as 
described in Section 1.7.2.2.2, and for the same slice a second, diffusion-weighted, image 
is acquired.  For this image, the so-called b-value [
𝑠
𝑐𝑚2
] indicates the size and strength of 
this diffusion gradient (Figure 1-10).   
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Figure 1-10: Diffusion sensitizing pulse gradient waveform 
A bipolar trapezoidal diffusion sensitizing gradient. Gm = maximum gradient amplitude, 𝜏 
= gradient ramp up/down time, 𝛿 = lobe duration, ∆ = diffusion time. 
 
 
𝑏 = (𝛾𝐺𝑚)
2[𝛿2 (∆ −
𝛿
3
) + 𝜏 (𝛿2 − 2∆𝛿 + ∆𝜏 −
7
6
𝛿𝜏 +
8
15
𝜏2)] 
(1-5) 
With 𝛾 = gyromagnetic ratio, Gm = maximum gradient, 𝜏 = gradient ramp up/down time, 
𝛿 = lobe duration and ∆ = diffusion time.  The b-value is chosen based on the confining 
medium and the free diffusion of the noble-gas used.  A good rule of thumb for b-value 
selection is (𝑏 ∙ 𝐴𝐷𝐶) ≅ 1 .95  This bipolar diffusion gradient works by dephasing the 
nuclear spins,93  this effectively encodes the initial position of the nuclei.  The negative 
portion of the gradient will rephrase the spins but it will not completely rephrase them as 
diffusion has occurred.  Thus, by relating the relative signal intensities in both the 
diffusion-weighted and non-diffusion-weighted images the ADC can be measured as 
shown in equation 1-7: 
 𝑆(𝑏)
𝑆0
= exp (−𝑏 ∙ 𝐴𝐷𝐶) (1-6) 
 
𝐴𝐷𝐶(𝑏) =  
ln (
𝑆0
𝑆(𝑏)
)
𝑏
 
(1-7) 
Where commonly used b-values for lung imaging range between 1.6 and 6.4 s/cm2 for 3He 
and 12 and 30 s/cm2 for 129Xe.  Figure 1-11 shows diffusion and non-diffusion-weighted 
3He ventilation images for the same slice in a subject with AATD.   
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Figure 1-11: Non-Diffusion and Diffusion-weighted 3He Ventilation Image 
When Equation 1-7 is applied to each voxel, a map of ADC can be generated. Figure 1-
12, shows the ADC map generated from the images in Figure 1-11. 
 
Figure 1-12: Static ventilation and ADC for AATD subject 
Static ventilation and slice matched ADC image for a representative AATD subject. 
Female, 58 years old. FEV1 = 32%pred, FEV1/FVC = 31%, RV/TLC = 62%, DLCO = 53 
%pred, ADC = 0.43 cm
2/s. 
 
3He ADC has been shown to correlate well with patient measurements of disease,94 
histological measurements of Lm
96 and CT measurements of emphysema.97 It is elevated 
in asthmatics post methacholine challenge, representing gas trapping.92 ADC is also related 
to lung inflation levels98 as well as patient age.99,100 There has been a large body of work 
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performed using 3He, there have been preliminary reports of 129Xe ADC in healthy 
volunteers and subjects with COPD101-103 with 129Xe ADC measurements correlating with 
histological measurements.104  
1.7.2.2.5 Multiple b-value ADC Magnetic Resonance Imaging 
By varying the b-values used, a set of multiple b-value images can be acquired for the same 
slice.  During an acquisition a molecule will either experience free unrestricted diffusion, 
or it will experience restricted diffusion due to the presence of airspace walls.  At different 
b-values varying number of molecules will experience restriction due to the presence of 
the airspace walls.  This technique can be used to probe varying length scales. Using the 
signal decay as a function of b-value measures a voxel-wise mean of airspace sizes.  This 
technique provides a more sensitive measurement, as compared to two b-value ADC 
measurements, of alveolar size 
1.7.2.3 Measurements of Alveolar Geometry using Multiple-b ADC 
Measurements of alveolar geometry can be made using assumptions of the noble gas 
displacement within the alveolus.  The assumption made in this thesis, based on previous 
work, is that the diffusion within the airways is anisotropic.  A cylindrical geometry of the 
alveoli and alveoli ducts is assumed. 
1.7.2.3.1 Weibel Model of Alveolar Geometry 
The primary geometrical representation of the acinar airways is the Weibel 
representation.18 In this representation (Figure 1-13), the airway is approximated as an 
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infinite cylinder (Figure 1-14) with inner and outer radii (r and R, respectively) and 8 
alveoli surrounding the cylinder with height h=R-r. 
 
Figure 1-13: Weibel representation of the acinar duct 
An acinar duct covered in a sleeve of alveoli. R = external airway radius, r = internal airway 
radius, L = alveoli length, h = alveoli sheath, DL = MRI longitudinal diffusion coefficient, 
DT = MRI transverse diffusion coefficient 
 
Figure 1-14: Infinite cylinder geometry 
The Weibel representation is considered as a cylindrical tube surrounded by a sleeve of 
alveoli.  R= external airway radius, r = internal airway radius. 
The outer cylinder represents a sleeve of alveoli surrounding the alveolar duct.  The 
diffusion of the noble gas within the acinar airways is assumed to be anisotropic, consisting 
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of both longitudinal (DL) and transverse (DT) diffusion coefficients.  The total MR signal 
acquired from a single voxel is:105 
 
𝑆(𝑏)=𝑆0𝑒𝑥𝑝 (−𝑏𝐷𝑇) (
𝜋
4𝑏(𝐷𝐿−𝐷𝑇)
)
1
2
𝛷 [(𝑏(𝐷𝐿 − 𝐷𝑇)
1
2] 
(1-8) 
Where 𝛷 is the error function (𝛷(𝑥) =
1
√𝜋
∫ 𝑒−𝑡
2
𝑑𝑡
𝑥
−𝑥
).  Using this MR signal as well as 
Monte-Carlo derived equations105 for the transverse and longitudinal diffusion are used to 
find geometrical expressions for the inner (r) and outer radii (R).  These geometrical values 
can then be used to find the alveolar length, surface-to-volume ratio and mean linear 
intercept as follows: 
 𝐿 = 2𝑅𝑠𝑖𝑛(
𝜋
8
) (1-9) 
 𝑆
𝑉
=
2𝜋𝑅𝐿 + 2𝜋(𝑅2 − 𝑟2) + 16(𝑅 − 𝑟)𝐿
𝜋𝑅2𝐿
 
(1-10) 
 
𝐿𝑚 = 4
𝑉
𝑆
 
(1-11) 
Measurements of airspace size (Lm) measured using this geometrical model have been 
shown to correlate with histology,106 show differences between elderly smokers and never-
smokers107,108 as well as correlate with disease severity. 
 Thesis Objectives 
In this thesis, my objective was to evaluate multiple b-value MRI in subjects with AATD 
and examine regional MRI biomarkers of emphysema.  This is important because in AATD 
disease manifests at a young age and longitudinal evaluation is important both clinically 
and in the process of development of novel treatments.  I hypothesized that subjects with a 
clinical diagnosis of AATD would show significantly elevated morphometry values as 
compared to ex-smokers with COPD and age-matched healthy elderly never-smokers.  I 
would expect to observe these differences since in AATD disease begins from birth and as 
such, would differ from smoking-related disease and that observed in senile emphysema. 
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To test this hypothesis, I performed a proof-of-concept demonstration in a small group of 
subjects with AATD, subjects with smoking related emphysema and a group of healthy 
age-matched never-smokers.  I compared whole lung diffusion weighted measurements of 
airspace enlargement across all three groups and examined these measurements regionally 
throughout the lung.  These measurements were also compared to standard clinical 
measurements such as spirometry and CT. 
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2 Chapter 2: Pulmonary 3He Magnetic Resonance Imaging 
Biomarkers of Emphysema in Alpha-1 Antitrypsin Deficiency 
The contents of this chapter have been accepted to Academic Radiology as an original 
research article authored by Eric Lessard, Heather M Young, Anurag Bhalla, Damien 
Pike, Khadija Sheikh, David G McCormack, Alexei Ouriadov and Grace Parraga titled 
Pulmonary 3He Magnetic Resonance Imaging Biomarkers of Regional Airspace 
Enlargement in Alpha-1 Antitrypsin Deficiency.  To better understand AATD related 
emphysema as measured by diffusion-weighted MRI we evaluated a small group of subjects 
with AATD using diffusion-weighted MRI, CT, spirometry, plethysmography and DLCO.  
We compared these measurements to those obtained in ex-smokers with smoking related 
emphysema and healthy age-matched never-smokers. 
 Introduction 
Alpha-1 Antitrypsin Deficiency (AATD), first described by Laurell and Eriksson in 1963,1 
is an autosomal co-dominant hereditary disorder caused by a mutation in the SERPINA1 
gene, which leads to dysregulation of neutrophil elastase.2  This commonly manifests as 
early-onset panlobular emphysema and affects approximately 1/5000 North Americans.2,3  
Respiratory failure accounts for 45-72% of deaths in patients with AATD.  Importantly, an 
increased risk of mortality may be predicted using CT biomarkers of emphysema2 and 
overall, outcomes are worse when patients cannot access augmentation therapy.4 
As is the case for smoking-related emphysema, there is no cure for AATD, although current 
AATD treatments aimed at slowing disease progression include exogenous alpha-1 
antitrypsin augmentation therapy.  X-ray computed tomography (CT) lung density 
measurements showed that augmentation therapy may slow the rate of emphysema 
progression in AATD patients4 - an important finding that may help guide treatment 
decisions given the high cost of intravenous augmentation treatment.2 However, while the 
CT measurement of emphysema progression was significantly lower in the treatment arm 
of the RAPID study, this did not correlate with similar changes in patient-related quality-
of-life measurements.4  This important limitation is also motivating the development of 
novel biomarkers and intermediate endpoints of AATD emphysema for novel treatments 
including gene therapy5 and pluripotent stem cells.6,7  
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The decline over time of the forced expiratory volume in 1 second (FEV1)
8-10 and the 
diffusing capacity of carbon monoxide (DLCO) are both considered as biomarkers of AATD 
lung disease. While highly variable,11 DLCO measurements correlate with pathology 
measurements12 and CT emphysema findings13 such as the relative area of the CT density 
histogram ≤ -950 Hounsfield units (RA950).14  More recently, pulmonary imaging 
biomarkers that exploit the diffusive motion of inhaled polarized gases such as 3He15 and 
129Xe16 have been measured in patients with emphysema17 using diffusion-weighted MRI 
pulse sequences.   
In particular, the 3He MRI apparent diffusion coefficient (ADC) was shown to reflect 
emphysema.15,18  Multiple b-value diffusion-weighted lung MRI17 also provides estimates 
of airway space geometry,17,19 based on the heterogeneous gas displacement in the terminal 
airways that are assumed to be cylindrical in shape.20  Such non-invasive MRI 
morphometry estimates17 provide a way to bypass or obviate the necessity for pathological 
analyses21-24 and may offer crucial information about lung disease progression, as well as 
treatment response.  Previous MRI studies in AATD patients25-28 showed there was no 
statistical difference in ADC values after two-years of follow-up26 but unfortunately, no 
morphometry data were acquired.  MRI morphometry modelling approaches were recently 
evaluated in COPD and AATD patients,29 but this work did not evaluate clinical and other 
regional biomarkers.  This is important because for AATD patients, emphysematous tissue 
destruction ensues early in life and panlobular emphysema is often severe by middle-age.   
Therefore, the aim of this study was to evaluate AATD patients using multiple b-value 
diffusion-weighted MRI as well as pulmonary function and CT measurements of 
emphysema.  We hypothesized that MRI measurements would be highly sensitive to 
airspace enlargement which would be significantly worse in AATD patients as compared 
to clinically similar ex-smokers with COPD. 
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 Materials and Methods 
2.2.1 Study Volunteers and Design 
All participants provided written informed consent to a study protocol approved by a local 
research ethics board and Health Canada.  Patients aged 40-90 years of age with a diagnosis 
of AATD and ex-smokers with COPD,  >10 pack-years smoking history and CT evidence 
of emphysema were recruited from a tertiary care centre and evaluated using spirometry, 
plethysmography, thoracic imaging, the St. George’s Respiratory Questionnaire (SGRQ) 
and 6-minute walk test (6MWT) during a single  two- hour visit.  CT evidence of 
emphysema was defined as an RA950 ≥ 6.8% as previously described.30  Older never-
smokers were also enrolled aged 60-80 years, <0.5 pack-years and no history of chronic 
lung disease or uncontrolled cardiovascular disease and completed all study measurements 
except for the SGRQ and 6MWT. 
2.2.2 Spirometry, Plethysmography, SGRQ and 6MWT 
Spirometry measurements were acquired according to the American Thoracic Society 
(ATS) guidelines31 using a whole body system (MedGraphics Corporation, St Paul, 
Minnesota, USA).  Body plethysmography was also performed for the measurement of 
lung volumes and DLCO was measured using the attached gas analyzer.  The SGRQ32 was 
used to establish overall quality of life and the 6MWT33 was used to measure exercise 
capacity. 
2.2.3 Image Acquisition 
MRI was performed on a whole body 3T system (MR750 Discovery, GEHC, Milwaukee, 
WI) with broadband imaging capability.34  3He MRI employed a whole body gradient set 
with maximum gradient amplitude of 50mT/m and a single-channel, rigid elliptical 
transmit/receive chest coil (RAPID Biomedical GmbH, Wuerzburg, Germany).  The basis 
frequency of the coil was 97.3 MHz and excitation power was 3 kW using an AMT 3T90 
RF power amplifier (GEHC).  Subjects were positioned supine in the scanner for both 1H 
and 3He MRI and instructed by a pulmonary function technologist to inhale a 1L gas 
mixture of 3He/N2 (20% 
3He by volume) from functional residual capacity (FRC), ensuring 
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a self-consistent lung volume of FRC+1L, with image acquisition performed under breath-
hold conditions as previously described.34  3He gas was polarized to 30-40% polarization 
using a spin-exchange optical polarizer (Polarean Inc, Durham, NC).  Diffusion-weighted 
3He MRI data were acquired using a multi-slice interleaved 2D gradient echo diffusion-
weighted sequence with a matrix size of 128x80, for seven 30mm coronal slices (900μs 
selective RF pulse, flip angle θ = 4°, TE = 3.9ms, TR=5.6ms, bandwidth=62.5kHz, in-
plane resolution = 3.125x3.125 mm2, b=0, 1.6, 3.2, 4.8, 6.4 s/cm2); the diffusion-
sensitization gradient pulse ramp up/down time was 500μs with a diffusion time of 1460μs.  
The potential for image artifacts associated with RF pulse “history”35 was addressed by 
using an optimal constant flip angle (4 degrees).36  A diffusion-sensitizing, gradient-step, 
k-space acquisition scheme starting at the maximum b-value was used to ensure that 
maximum MR signal was acquired for diffusion-weighted images at greater b-values.  All 
five b-value images were acquired during a single 15s breath-hold.   
Thoracic CT was acquired on a 64-slice Lightspeed VCT scanner (General Electric Health 
Care, Milwaukee, Wisconsin) (64 × 0.625 mm, 120 kVp, 100 effective mA, tube rotation 
time=500 msec, and a pitch=1.0).  A single spiral acquisition was performed with subjects 
in the supine position and at inspiration breath-hold after inhalation of a 1.0L N2 bag from 
FRC (NS, AATD1, 6-8) or at full inspiration (COPD, AATD2-5).  CT Images were 
reconstructed using a slice thickness of 1.25 mm with a standard convolution kernel.  The 
total effective dose for an average participant was 1.8 mSv according to manufacturer 
settings and Imaging Performance Assessment of CT (ImPACT) CT patient dosimetry 
calculator based on software from the Health Protection Agency of the United Kingdom 
(NRPB-SR250).   
2.2.4 Image Analysis 
To measure MRI ventilation defect percent (VDP), we used semi-automated segmentation 
software (MATLAB R2014b; MathWorks, Natick, Mass) as previously described,37 
utilizing an independently acquired image without diffusion weighting.  3He MRI ADC 
maps were generated as described previously38,39 and the Weibel acinar duct model20 was 
used to generate morphometry estimates as previously described.17,23,40  Multiple-b-value 
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measurements39 of the 3He diffusion-attenuated MR signal were used to derive 
morphological parameters of the acinar airway, including external radius (R), internal 
radius (r), alveolar length (L), depth of alveolar sleeve (h), surface area-to-volume ratio 
(S/V) and mean linear intercept (Lm).  To model the severe emphysema that accompanies 
AATD lung disease, we did not constrain R or r, nor their ratio, unlike previous work in 
elderly never-smokers and COPD patients.39  The cylindrical model was used based on 
previous work17,41,42 and based on the fact that in AATD patients, normal lung development 
and alveolarization is expected.43  Regional ADC and morphometry measurements were 
computed using custom-built software generated using MATLAB software whereby the 
carina was identified in the b = 0 image and used to segment the lung into apical and basal 
regions. 
CT airway count, RA950, and low attenuating clusters (LAC) with CT density values ≤ -
950 HU44 were determined using Pulmonary Workstation 2.0 (VIDA Diagnostics Inc., 
Coralville, IA).  LAC was calculated using the log-log relationship44 between the 
cumulative frequency distribution of emphysematous lesions (# of lesions) and cluster size 
(size of lesions) according to the power law relationship Y = XLAC  (Y = cumulative 
frequency distribution, X = size of lesions).  Lower LAC values (more negative) are 
indicative of smaller, and fewer, clusters of emphysematous lesions whereas greater LAC 
values suggest fewer and larger lesions.  Graphically, this is illustrated as spheres 
representing the relative size of emphysematous lesions, with larger spheres indicating 
larger and connected low attenuating areas.  Regional RA950 was generated using the carina 
to segment the lung into apical and basal lung regions. 
2.2.5 Statistical Analysis 
All statistical analyses were performed using IBM SPSS Statistics, Version 24 (IBM, 
Armonk, NY, USA).  Comparisons between groups were performed using a multivariate 
analysis of variance (MANOVA) with post-hoc Tukey honest significant difference test.  
Results were considered significant when the probability of making a Type 1 error was < 
5% (p < .05). 
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 Results 
Table 1 provides demographic information for the AATD patient subgroup (n=8, 57±7 
years), ex-smokers with COPD (n=8, 77±6 years) and never-smokers (n=5, 64±2 years).  
There was significantly different FEV1 (p = .007), FEV1/FVC (p < .0001), RV (p = .03) 
and DLCO (p < .0001)  for AATD patients as compared to never-smokers but there were no 
significant differences between AATD and COPD patients except for age (p < .0001) and 
SGRQ (p=.01).  COPD patients were significantly older and had a significantly better 
SGRQ score indicating better quality of life.  
 
Table 2-1: Demographic and pulmonary function measurements 
Parameters 
(±SD) 
Never-
Smoker 
n=5 
COPD 
Ex-Smoker 
n=8 
AATD 
n=8 
NS-COPD NS-AATD 
AATD-
COPD 
Female n 5 1 3 - - - 
Age yr 64 (2) 77 (6) 57 (7) .001 .2 <.0001 
BMI kg/m2  24 (2) 26 (3) 27 (5) .8 .6 .9 
FEV1 %pred 101 (9) 72 (34) 47 (20) .1 .007 .2 
FVC %pred 96 (9) 94 (26) 78 (21) .9 .4 .4 
FEV1/FVC % 80 (1) 52 (11) 47 (12) <.0001 <.0001 .8 
RV %pred 84 (24) 147 (50) 170 (65)* .1 .03 .7 
TLC %pred 97 (13) 110 (15) 129 (37)* .2 .2 .9 
RV/TLC % 35 (6) 50 (11) 51 (13)* .05 .06 .9 
DLCO %pred 95 (14) 55 (16) 44 (19)* .002 <.0001 .4 
6MWD m ND 380 (88) 385 (80) ND ND .9†† 
SGRQ ND 30 (18) 55 (17) ND ND .01†† 
FEV1=forced expiratory volume in 1 second; %pred=percent predicted; FVC=forced vital 
capacity; RV=residual volume; TLC=total lung capacity; DLCO=diffusing capacity of the 
lungs for carbon monoxide; 6MWD=six-minute walk distance; SGRQ=St. George’s 
Respiratory Questionnaire total score. MANOVA between groups with post-hoc Tukey 
HSD for multiple comparisons. ††Unpaired t-test between COPD and AATD; *n=7.  
Figure 1 shows CT airway trees and coronal centre slice low attenuating cluster maps as 
well as coronal centre slice MRI ventilation and ADC maps for representative participants 
in each subgroup.   For the two representative never-smokers, there was little or no 
evidence of CT low attenuating regions or clusters while MRI ADC maps were 
homogeneous with normal ADC values and ventilation maps reflected relatively few, small 
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ventilation defects.  In the two representative COPD patients, there were numerous CT low 
attenuating regions and low attenuating clusters with large ventilation defects and abnormal 
ADC values, mainly in the apical lung.  In the two representative AATD patients, CT low 
attenuating regions and clusters dominated in the lower lobes and this was concomitant 
with highly abnormal MRI ADC values (shown in yellow), mainly in the basal lung.  
 
Figure 2-1: Thoracic CT and MRI for Never-smokers, COPD and AATD 
Participants 
Left panels: CT RA950 maps (yellow pixels corresponding to voxels <-950 Hounsfield 
Units) and CT LAC maps; Right panels: 3He static ventilation (Cyan) co-registered with 
1H MRI; 3He MRI apparent diffusion coefficient (ADC) maps. NS-1 is female age 63 years 
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with FEV1=109 %pred, DLCO=103 %pred, RA950=0.19 %, ADC=0.25 cm
2/s; NS-4 is female 
age 64 years with FEV1=108 %pred, DLCO=99 %pred, RA950=0.13 %, ADC=0.29 cm
2/s; 
COPD-4 is male age 75 years with FEV1=30 %pred, DLCO=31 %pred, RA950=26 %, ADC 
=0.50 cm2/s; COPD-6 is male age 84 years with FEV1=52 %pred, DLCO=47 %pred, RA950=24 
%, ADC= 0.50 cm2/s; AATD-1 is male age 67 with FEV1=58 %pred, DLCO=50 %pred, 
RA950=19 %, ADC=0.57 cm
2/s; AATD-5 is male age 50 with FEV1=25 %pred, DLCO=32 
%pred, RA950=27 %, ADC=0.47 cm
2/s. 
 
Figure 2 shows the qualitative differences in RA950, ADC and Lm maps for representative 
never-smokers, AATD and COPD patients.  For example, for NS-2 and NS-5, there was 
no evidence, based on RA950 or MRI ADC, of airspace enlargement or emphysema.  
However, there was a difference in mean Lm for these two never-smokers with lower, 
darker voxels for NS-5, a female aged 63 years as compared to NS-2 a female never-smoker 
also aged 63 years and the reasons for these differences were not evident.  For COPD and 
AATD patients, there was CT evidence of emphysema in the upper (COPD) and basal lung 
(AATD).  ADC and Lm maps also show brighter colours that reflect enlarged airspaces that 
in COPD patients predominated in the upper lobes. In AATD-3, there was highly abnormal 
Lm, homogeneously distributed throughout the ventilated portions of the lung.  For patient 
AATD-2, there was very poor basal lung ventilation and therefore no ADC or 
morphometry values could be reported from these regions, although CT showed moderate 
basal lung emphysema.     
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Figure 2-2: Morphometry Maps for Representative Never-smokers, COPD ex-
smokers and AATD Patients 
Left panels:MRI static ventilation (Cyan) co-registered with 1H MRI; CT RA950 maps 
(yellow pixels corresponding to voxels <-950 Hounsfield Units). Right panels: 3He MRI 
apparent diffusion coefficient (ADC) and mean linear intercept (Lm) maps. NS-5 is female 
age 63 years with FEV1=106 %pred, DLCO=80 %pred, RA950=0.19 %, ADC=0.27 cm
2/s, 
Lm=180 µm; NS-2 is female age 63 years with FEV1=94 %pred, DLCO=113 %pred, 
RA950=0.44 %, ADC= 0.28 cm
2/s, Lm=240 µm; COPD-5 is female age 72 years with 
FEV1=56 %pred, DLCO=59 %pred, RA950= 8 %, ADC = 0.33 cm
2/s, Lm=310 µm; COPD-2 is 
male age 79 years with FEV1=126 %pred, DLCO= 62 %pred, RA950= 11%, ADC= 0.41 cm
2/s, 
Lm=540 µm; AATD-2 is male age 57 with FEV1= 37 %pred, DLCO= ND, RA950= 23 %, 
ADC= .46 cm2/s, Lm=680 µm; AATD-3 is female age 62 with FEV1=61 %pred, DLCO=21 
%pred, RA950= 31%, ADC= 0.67 cm
2/s, Lm=1200 µm. 
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Table 2 and Figure 3 provide a summary of quantitative imaging measurements for each 
subgroup and Table 3 provides all imaging data by participant. As shown in Table 2, AATD 
subjects had significantly elevated whole lung ADC (p= .03), basal lung ADC (p=.045) Lm 
(p=.001) and diminished S/V (p=.01) as compared to COPD ex-smokers.  RA950 was 
significantly elevated in the basal portion of the lungs as compared to the apical portion in 
AATD subjects only (p = .03).  Figure 3 provides box and whisker plots for whole lung 
(top panel), apical (middle panel) and basal (bottom panel) RA950, Lm and ADC by 
subgroup.  In COPD and AATD patients, there was significantly different whole lung, 
apical and basal Lm and ADC, but there was no significant difference in whole lung, apical 
or basal RA950.  Receiver operating curve (ROC) analysis was also performed between the 
AATD and COPD subgroups for Lm, (AUC = .95, p = .002), ADC (AUC = .85, p = .02) 
and RA950 (AUC = .71, p = .16). 
Table 2-2: Pulmonary MRI and CT measurements 
    Significance of Difference (p) 
Parameters (±SD) 
Never- 
Smoker 
n=5 
COPD 
Ex-Smoker 
n=8 
AATD 
n=8 
NS-
COPD 
NS-
AATD 
AATD-
COPD 
WL ADC cm2/s .27 (.02) .41 (.07) .51 (.08) .005 <.0001 .03 
Apical ADC cm2/s .26 (.02) .42 (.07) .48 (.07) .002 <.0001 .3 
Basal ADC cm2/s .27 (.02) .41 (.07) .53 (.11) .03 <.001 .045 
VDP % 2 (1) 23 (13) 28 (16) .03 .01 .8 
WL Lm µm 220 (80) 480 (250) 890 (330) .04 <.0001 .001 
Apical Lm µm 210 (80) 500 (250) 840 (310) .02 <.0001 .001 
Basal Lm µm 220 (80) 480 (230) 950 (310) .09 <.0001 .001 
S/V cm-1  200 (50) 110 (50) 50 (20) <.0001 <.0001 .01 
WL CT RA950 % 0.2 (0.2) 13 (8) 20 (9) .01 .001 .3 
Apical CT RA950 % 0.2 (0.1) 11 (7) 13 (8) .02 .007 .8 
Basal CT RA950 % .2 (.2) 14 (8) 21 (10) .02 .001 .2 
CT LAC  -2.1 (.4) -1.7 (.1) -1.6 (.2) .1 .01 .4 
Airway count 151 (26) 112 (25) 120 (17) .02 .1 .5 
WL=whole lung; VDP=ventilation defect percent; ADC=apparent diffusion coefficient; 
R=external airway radius; r=internal airway radius; h=alveolar sheath; Lm=mean linear 
intercept; RA950=relative area of the CT density histogram of attenuation values <-950 
Hounsfield Units; LAC=low attenuating clusters. MANOVA between groups with post-
hoc Tukey HSD for multiple comparisons. 
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Figure 2-3: Regional Imaging Biomarkers 
Box and Whisker Plots show mean and standard deviation. NS=never-smoker, 
COPD=COPD ex-smoker, AATD=alpha-1 antitrypsin deficiency. RA950=relative area of 
the CT lung density histogram with attenuation values <-950 HU, Lm=mean linear 
intercept, ADC=apparent diffusion coefficient. Group comparisons performed with an 
MANOVA and multiple comparisons corrected with a post-hoc Tukey HSD test. 
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Table 2-3: MRI and CT Measurements by Participant 
Parameter 
(±SD) 
ADCWL 
cm2/s 
ADCAp 
cm2/s 
ADCBa 
cm2/s 
VDP  
% 
Lm(wl)  
µm 
Lm(Ap)  
µm 
Lm(Ba) 
µm 
RA950  
% 
LAC 
NS-1 .25 (.04) .25 (.03) .25 (.04) 2 190 (80) 200 (90) 180 (70) 0.2 -1.6 
NS-2 .28 (.04) .26 (.03) .29 (.04) 2 240 (80) 230 (70) 250 (90) 0.4 -2.4 
NS-3 .24 (.02) .24 (.02) .24 (.02) 2 200 (60) 190 (50) 200 (60) 0.1 -2.4 
NS-4 .29 (.03) .29 (.03) .29 (.03) 2 290 (80) 280 (80) 300 (80) 0.1 -1.6 
NS-5 .27 (.03) .26 (.02) .27 (.03) 3 180 (90) 170 (70) 180 (100) 0.2 -2.3 
All NS .27 (.02) .26 (.02) .27 (.02) 2 (1) 220 (80) 210 (80) 220 (80) 0.2 (0.2) -2.1 (0.4) 
COPD-1 .36 (.05) .36 (.05) .35 (.05) 16 330 (130) 360 (150) 290 (110) 8 -1.9 
COPD-2 .41 (.05) .43 (.04) .39 (.05) 16 540 (280) 610 (320) 470 (200) 11 -1.7 
COPD-3 .35 (.03) .36 (.03) .34 (.04) 5 370 (150) 410 (160) 330 (120) 8 -1.9 
COPD-4 .50 (.08) .54 (.07) .48 (.08) 45 670 (350) 750 (350) 630 (340) 26 -1.7 
COPD-5 .33 (.04) .30 (.04) .34 (.04) 14 310 (120) 290 (110) 320 (130) 8 -1.9 
COPD-6 .50 (.05) .56 (.05) .54 (.06) 31 790 (380) 630 (330) 960 (350) 24 -1.8 
COPD-7 .39 (.07) .43 (.08) .39 (.07) 30 370 (220) 410 (220) 360 (210) 14 -1.6 
COPD-8 .43 (.06) .43 (.06) .43 (.06) 25 490 (240) 510 (250) 480 (230) 8 -1.6 
All COPD .41 (.07) .42 (.07) .41 (.07) 23 (13) 480 (250) 500 (250) 480 (230) 13 (8) -1.7 (0.1) 
AATD-1 .57 (.09) .51 (.06) .60 (.13) 27 1000 (410) 920 (440) 1100 (330) 19 -1.4 
AATD-2 .46 (.08) .39 (.07) .51 (.10) 53 680 (320) 610 (280) 940 (350) 23 -1.9 
AATD-3 .67 (.10) .60 (.08) .73 (.12) 13 1200 (360) 1200 (380) 1270 (330) 31 -1.3 
AATD-4 .53 (.08) .52 (.07) .56 (.08) 17 1110 (220) 1070 (220) 1140 (210) 19 -1.5 
AATD-5 .47 (.12) .48 (.10) .46 (.12) 49 700 (350) 700 (360) 700 (340) 27 -1.6 
AATD-6 .41 (.09) .41 (.06) .41 (.10) 10 710 (190) 720 (190) 710 (190) 3 -1.9 
AATD-7 .44 (.09) .48 (.06) .39 (.12) 21 840 (260) 950 (240) 780 (240) 14 -1.4 
AATD-8 .53 (.04) .45 (.03) .57 (.05) 37 810 (440) 520 (270) 960 (430) 22 -1.7 
All AATD .51 (.08) .48 (.07) .53 (.11) 28 (16) 890 (330) 840 (310) 950 (310) 20 (9) -1.6 (0.2) 
 
SD=standard deviation; ADC=apparent diffusion coefficient; WL=whole lung; Ap=apical lung; Ba=basal lung; VDP=ventilation defect percent; Lm=mean 
linear intercept; S/V=surface to volume ratio; RA950=relative area of the CT density histogram with attenuation values < -950 HU; LAC=low attenuating 
clusters 
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 Discussion 
For patients with AATD, pulmonary function tests and thoracic CT measurements of 
emphysema are typically used to evaluate disease severity, disease progression and 
response to therapy.  Unfortunately, such measurements are relatively insensitive to small 
changes over time and do not fully explain longitudinal changes in symptoms and quality 
of life.  Therefore, here our objective was to evaluate inhaled-gas MRI biomarkers of 
emphysema in AATD patients and compare these with CT and other clinical measurements 
of emphysema in elderly never-smokers and COPD patients with smoking-related 
emphysema.21,23  We measured MRI and CT biomarkers of emphysema and observed: 1) 
abnormal MRI ADC and Lm measurements that were significantly worse in AATD as 
compared to COPD patients in whom CT RA950, airway count and other pulmonary 
function test measurements were not significantly different, 2) differences in ADC and Lm 
in elderly never-smokers with normal CT, reflecting different senile emphysematous 
changes, and, 3) highly abnormal basal lung MRI Lm values in AATD patients although 
there was no basal lung ventilation in some AATD patients.  
As might be expected, in AATD patients, MRI measurements of ventilation (VDP) and 
parenchyma microstructure (ADC) were abnormally elevated in the basal lung.  Ventilation 
defects were prominent in participants AATD-1, AATD-2 and AATD-5 and this was 
consistent with the notion that in severe emphysema, the time constants for lung filling 
were longer than the MRI acquisition timeframe.  Ventilation defects were also spatially 
related to regions with abnormal RA950 and this was previously shown in severe COPD.
45,46  
In particular, in patient AATD-2, there were large ventilation defects, which was coincident 
with a highly abnormal SGRQ score of 80.  It is important to note that in this patient, FEV1 
did not reflect the severity of emphysema, nor symptoms.  In contrast, for Subject AATD-
6, there was imaging evidence of very mild emphysema and this was in agreement with 
modestly abnormal SGRQ, 6MWD and DLCO values.   
We were surprised to observe that there was no difference in pulmonary function test and 
CT biomarkers of emphysema in AATD patients compared to COPD ex-smokers in whom 
there were significantly different Lm, S/V and ADC (WL and basal) measurements.  This 
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may be due to different underlying pathophysiological mechanisms for panlobular 
emphysema, common in AATD patients, as compared to centrilobular emphysema more 
common in current or previous smokers without AATD.  There was no difference in airway 
count between the COPD and AATD subgroups.  This is somewhat surprising because 
airway count has been suggested as a unique biomarker of COPD in smokers and ex-
smokers and is an independent predictor of BMI, airflow obstruction, dyspnea, and exercise 
capacity (BODE) index47 in COPD patients. The airway count result may stem from a small 
sample size but we also note that there was a difference between COPD and NS participants 
for airway count.  This may suggest that similar to ex-smokers with COPD, in AATD 
emphysema, terminal airways are also occluded or obliterated so that they cannot be 
resolved using CT.  To our knowledge this is a novel result.  It is also noteworthy that for 
AATD patients with greater overall MRI evidence of airspace enlargement, suggestive of 
emphysema, there was greater apical lung ADC which supports the notion that as AATD 
worsens, both the basal and apical lung are involved.  It is important to point out however 
that not all AATD patients present with basal-dominant emphysema48 and this was also 
observed here in AATD-7, with greater apical as compared to basal ADC and Lm.  Elevated 
apical Lm and ADC in AATD-7 may be explained by a 43 pack-year smoking history, 
although there is no apical-dominant disease in patient AATD-3 (35 pack years) or patient 
AATD-8 (30 pack years).  Furthermore, the range of Lm and ADC values for NS may be 
indicative of different senile emphysematous changes.   While NS-1 and NS-5 both have 
smaller airspaces as measured by MRI than age matched NS-4 who has airspaces 
approximately 50% larger (190µm vs 290µm).  The reasons for this difference is not clear, 
but differences in unappreciated environmental exposures or other undetermined causes of 
accelerated lung aging in these individuals is possible. 
While these cross-sectional results provide good evidence of the feasibility of acquiring 
MRI biomarkers in AATD patients, they also provide a better understanding of regional 
emphysema and the relationship of emphysema with quality of life in these patients.   For 
example, perhaps because of the small sample size, SGRQ was the only clinical 
measurement that was significantly different in COPD and AATD patients.  This finding 
is consistent with previous work that showed the relationship of modestly diminished DLCO 
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with MRI biomarkers in ex-smokers with normal spirometry but abnormal SGRQ and 
6MWD.49  The elevated Lm, ADC and S/V measurements in AATD patients here also 
revealed the sensitivity of MRI biomarkers to subtle differences in airspace enlargement 
even in the absence of CT measurement differences.  Our results suggest that ADC may 
better distinguish airspace enlargement observed in NS participants and COPD participants 
while Lm may better distinguish between emphysematous lesions in COPD and AATD 
patients.  We note that previous work50 reported a similar finding for ADC and Lm in ex-
smokers with and without emphysema using ROC analysis with AUC = .9 (p=.002) for 
ADC, and .91 (p=.02) for Lm, respectively. Taken together, these data suggest that MRI-
derived Lm captures subtle differences between panlobular (AATD) and centrilobular 
(COPD) emphysema.  We think the sensitivity of MRI can play an important role in 
measuring disease progression in longitudinal studies or response to therapy in clinical 
trials with small sample sizes, such as evaluated here.  Similar to CT biomarkers of 
emphysema, MRI biomarkers of airspace enlargement may play an important role in 
measuring emphysema in AATD patients undergoing augmentation therapy which is 
especially important given the high cost of treatment. 
We must acknowledge a number of study limitations and caveats.  It is important to note 
that a shortcoming of inhaled gas MRI is the reliance of measurements on lung regions that 
are well-ventilated.  In other words, where there are ventilation defects, no values can be 
reported; this generates a bias towards normal values from ventilated lung (in this case, 
apical lung).  Furthermore, for longitudinal evaluation it is important to ensure that lung 
inflation levels is consistent between scans, such as in the RAPID trial4, and this would 
certainly help with reproducibility and measurement precision.  It is also important to note 
that diffusion-weighted MRI reproducibility was previously evaluated by three different 
groups including the measurement of precision of ADC values (28, 51, 52) and Lm values 
(53).   These previous results provided a strong foundation for our approach and for future 
longitudinal studies.  These factors are important to consider if the techniques evaluated 
here are to be used clinically to monitor disease progression in AATD patients over time 
and those undergoing augmentation therapy.  Using CT emphysema measurements, 
augmentation therapy has been shown to slow the rate of lung tissue density loss and we 
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expect that MRI biomarker sensitivity can also be exploited for longitudinal evaluations of 
this patient population. We also note that for one participant who was severely impaired, 
plethysmography measurements and the 6MWT could not be undertaken; this is certainly 
something worth considering for longitudinal studies in AATD patients.  It is important to 
recognize that we used a cylindrical airway geometry model to estimate MRI Lm which 
may not be appropriate in the case of very severe emphysema.  Recent work examined the 
use of three different emphysema modelling approaches and showed good agreement 
between the cylindrical model and another model which made no geometrical 
assumptions.29  This and the fact that we did not constrain internal acinar duct radial 
parameters suggests that the comparisons made here between COPD and AATD patients 
are physiologically relevant.  In addition to this, these results are in agreement with recent 
morphomic measurements,23 taken at 1.5T, using histology and diffusion-weighted MRI 
which measured S/V ratios of approximately 250 cm-1 for healthy controls, 100-140 cm-1 
for mild emphysema and 50-55 cm-1 for severe emphysema.  These findings are in good 
agreement with S/V values measured here in never-smoker (S/V=200±50 cm-1), COPD 
(S/V=110±50 cm-1) and AATD subjects (S/V=50±20 cm-1).  We should also underscore 
the age difference between the study groups which is a limitation of the study because it 
was previously established54 that MRI ADC and Lm values are age-dependent values.  
Importantly, the AATD participants we evaluated were significantly younger than the 
COPD patients, even though lung disease severity based on imaging biomarkers was 
greater.  This suggests that the elevated ADC and Lm values in the AATD patients were 
not due to age differences. 
An important limitation is the fact that MRI was performed at FRC+1L in all participants 
(i.e., the lung inflation volume was not normalized across subjects).  This is important 
because lung inflation volume, alveolar inflation and ADC/morphometry values are 
related.  In our study, MRI was performed at FRC+1L in all participants, with coaching by 
a pulmonary function technologist, to ensure that lung volumes were reproducible within 
and between participants.  This lung volume has been used extensively in the past which 
allows for comparison with previous studies and this is, in our experience a relatively 
straightforward maneuver for patients with respiratory disease.  We note however, that for 
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NS-2 and NS-5, the FRC+1L volume was very similar (FRC+1L = 3.8±0.2L) and there 
was no significant correlation between Lm and TLC (p=.7) and Lm and FRC+1L (p=.9). 
This present study builds upon previous MRI studies in AATD patients25-28 that evaluated 
ADC measurements and their changes over relatively short periods of time.  Previous work 
in COPD patients50 and healthy volunteers39,51 provides a foundation for the current study 
that extends the two b-value ADC approach with a single breath whole lung multiple b-
value morphometry approach.29  MRI provides similar and complementary information to 
CT with the advantage of being free of ionizing radiation, which is important for AATD 
patients who are diagnosed at relatively young ages. These patients have the opportunity 
to undergo augmentation therapy; MRI biomarkers that provide sensitive measurements of 
airspace enlargement can be considered for these treatment studies and longitudinal 
evaluations. MRI also offers novel structure-function biomarkers including measurements 
of parenchyma microstructure that correlate with histological samples.21,23,24  Moreover, as 
we transition to inhaled 129Xe gas as contrast,16  it is important to note that dissolved-phase 
129Xe MRI may be employed to simultaneously estimate ventilation, perfusion52 and 
surrogate measurements of DLCO.
53  This information may be very helpful in studies that 
evaluate augmentation therapy and other AATD treatments for which direct evidence of 
efficacy3,4 has been difficult to ascertain. 
In summary, MRI biomarkers of emphysema were significantly different in AATD 
subjects as compared to age-matched never-smokers and older ex-smokers with smoking-
related emphysema.  Importantly, the significantly different and abnormal Lm values in 
AATD patients, who were not significantly different from COPD patients with respect to 
pulmonary function tests and CT emphysema measurements, reveals the sensitivity of MRI 
emphysema measurements in AATD patients for whom lifelong monitoring is required. 
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3 Chapter 3: Conclusions and Future Directions 
 Overview and Research Questions 
This thesis sought to provide measurements of pulmonary airspace enlargement using 
diffusion-weighted MRI in COPD and AATD.  This is crucial as quantification of lung 
structure can be considered the gold standard in evaluation of response to treatment in 
COPD.1  COPD is a disease that has tremendous costs both economically and socially in 
Canada2 and worldwide.3 
 Summary and Conclusions 
In this thesis, I examined a sample of patients with AATD.  I demonstrated that, by using 
a multiple-b value diffusion-weighted MRI approach, I could obtain similar, and 
complimentary, information to CT; this finding is important in the case of AATD where 
disease begins at a young age making longitudinal evaluation of disease using CT 
unattractive due to cumulative dose effects.  I compared these patients to age-matched 
healthy never-smokers and the AATD subjects were significantly worse as measured by 
both CT (LAC and RA950) and 
3He diffusion MRI (VDP, ADC and morphometry).  In 
addition, I compared these AATD patients to a group of ex-smokers with smoking related 
emphysema.  These groups showed no differences in spirometry, CT measurements, 
ventilation measurements or exercise capabilities but the AATD group was statistically 
worse in terms of perceived quality of life, whole lung and basal ADC, and morphometry 
values (whole lung, apical and basal).  These results showed that using a small sample 
population it is possible to elucidate differences in disease severity by using diffusion-
weighted MRI. Ultimately, this approach may provide a method of performing smaller 
clinical trials examining treatment efficacy in AATD drug development. 
In summary, I have 1) examined a patient population who would greatly benefit from 
inhaled noble-gas morphometry as a sensitive measurement of disease severity, 2) 
demonstrated that whole lung multiple b-value measurements of airspace enlargement are 
feasible in this population and 3) demonstrated that this technique can differentiate between 
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smoking-related disease and AATD-related disease even in the absence of spirometry or 
CT differences. 
 Limitations 
Study specific limitations are discussed in detail in Chapter 2 but the most important 
limitations from Chapter 2 and a few major limitations will be discussed in more detail 
here.   
In Chapter 2 we explored a small sample of AATD patients (n=8) and observed 
significantly elevated morphometry values of airspace enlargement.  These are elevated as 
compared to COPD ex-smokers and age-matched elderly never-smokers.  The AATD 
subjects showed no difference between the COPD ex-smokers as visualized using CT or 
using standard clinical airflow measurements. 
Outside of the study specific limitations, there exist limitations inherent to the inhaled 
noble-gas morphometry method.  Inhaled noble-gas morphometry measurements are 
inherently reliant on gas dispersion throughout the lungs.  Essentially, in regions of 
ventilation defect, morphometry measurements cannot be acquired.  When reporting a 
whole lung mean value, this will skew the measurement towards the healthy lung tissue 
(regions which are ventilated).  Furthermore, this excludes fractions of the lung for 
quantitative evaluation, and unfortunately non-ventilated regions cannot distinguish 
between emphysematous destruction, mucus clogged airways or other reasons for lack of 
ventilation.   
Another major limitation of the ADC technique is the intrinsic variation in ADC 
measurements that depend on gradient timing parameters.  The temporal profile of the 
applied bipolar diffusion gradients affects the ADC measurement and as such it is 
important to keep this consistent between scans.4,5  Furthermore there is the effect of field 
strength on ADC measurements.4  Briefly, in previous work the authors observed 
significantly elevated ADC measurements obtained in the same subjects (n=5, healthy 
volunteers) at 3T versus 1.5T.  The authors concluded this difference was due to 
susceptibility-induced field inhomogeneities. Although, these differences could be 
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accounted for by differences in scanner manufacturers (Philips 3T and GE 1.5T).  
However, this is still important to keep in mind when comparing measurements across 
centres as a difference in obtained ADC may be due to a difference in field strength or 
possibly scanner manufacturer.  Other factors, such as the spatial profile of the magnetic 
field, surface relaxation and surface permeability, also have an effect on the ADC 
measured.5  
Perhaps the most important limitation of this thesis work is the availability and cost of 3He 
and limited access to polarization equipment.  This can be partially resolved through 
transition to 129Xe which is more cost effective and naturally abundant. However, until 
recently similar levels of polarization could not be achieved with 129Xe as could be 
achieved with 3He.  129Xe still needs to be polarized prior to use but can reach required 
polarization much quicker (~45 minutes) versus 3He (~18 hours) which makes it attractive 
for performing serial scans in a single day.  However, 129Xe that has been polarized and 
prepared for administration must be used as it now resides outside of the gas cell.  3He 
however does not exit the gas cell until immediately before administration meaning in the 
event of scan cancelation or failures up until the moment of administration 3He can still be 
recovered and used later whereas 129Xe will be wasted, or at best needs to be recycled. 
 Future Directions 
3.4.1 Overcoming Issues Related to Gas Dispersion 
A method of overcoming gas dispersion issues with regards to measuring tissue 
microstructure has been explored using modelled Carr-Purcell-Meiboom-Gill (CPMG) 
inter-echo time R2 dispersion
6 unfortunately this method has yet to transition into in vivo 
measurements.  Briefly, in this work the authors tested an in silico model of alveoli as 
spherical airspaces and derived equations for the relaxation rate R2, the transverse 
relaxation rate.  They tested their model against deflated rat lungs and demonstrated good 
agreement between the mean alveolar radius as measured using this technique (31.5 ± 13 
µm) and literature (34 µm). 
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3.4.2 Accelerated Imaging 
Diffusion-weighted MRI with multiple-b values (5 values) may require as much as 16 
seconds acquiring 7 slices.  With parallel imaging or compressed sensing, the scan speed 
can be greatly increased and the possibility of greater number of slices (>14) can be 
achieved.  With this there would no longer be a requirement of taking a separate static 
ventilation scan to obtain VDP measurements.  This would in theory halve the required 
volume of gas used to obtain a full set of information that MRI can provide (VDP, ADC, 
morphometry).  This is especially important both in a clinical setting and a research setting 
as the cost of 3He continues to rise due to its natural scarcity.  Another possible benefit 
would be towards isotropic voxel sizes.  Currently 3.125x3.125x30 mm3 are common for 
diffusion-weighted scans, and 3.125x3.125x15 mm3 are common for static ventilation 
scans.  With a large increase in scan speed, smaller voxels would be possible.  Preliminary 
work has been done with acceleration factors up to x10 with only some lost details as 
compared to no acceleration.7 
Implementation of parallel imaging, using a multi-channel receive array, would allow an 
increase in scan speed.  However, it comes with limitations in reduced FOV and aliasing 
artifacts.  Using the known spatial information of the coils the resulting images are 
“unfolded” and the original image is reconstructed.  Preliminary work has been performed8 
using generalized autocalibrating partially parallel acquisitions (GRAPPA) and an 8-
channel receive coil, which demonstrated that lung morphometry can be calculated using 
parallel imaging without significant differences in measurements.  They conclude that even 
though the work was performed using 3He that it could be generalized to 129Xe.  This in 
turn makes this technique more clinically translatable. 
3.4.3 The Transition to 129Xe 
Much of the work in noble-gas lung morphometry has been done using 3He due to its high 
gyromagnetic ratio and achievable polarization levels.  However, with the inevitable 
transition from 3He to 129Xe due to the lower cost and greater natural abundance of 129Xe, 
it is important to ensure that methods can also be translated.  In our lab9 we have compared 
three different acinar duct models relying on 3He diffusion.  The cylindrical model used in 
 61 
 
this thesis already has a theoretical formulation for the use of 129Xe and can be readily 
translated.10  Another geometrical model assuming spherical symmetry was explored 
which is based on varying the diffusion time as opposed to b-value during the scan and can 
be readily transitioned to use with 129Xe.  The third model, the stretched exponential model, 
is without geometrical assumptions, nor assumptions regarding gas diffusivity and due to 
this would also be translatable to 129Xe.  These considerations are important if this method 
is to be used to longitudinally evaluate patients with AATD. 
Outside of technical challenges, there is still much work to be done identifying potential 
biomarkers of disease using diffusion-weighted MRI in the lung.   
3.4.4 Functional Diffusion Maps of the Lungs 
There has been work in other organs, specifically in the brain examining the change in 
ADC measurements in an imaging voxel across periods of time.11  Functional Diffusion 
Maps (FDM), are co-registered ADC maps that stratify regions of the brain into three 
distinct categories, i.e., regions which have increased ADC, unchanged ADC or decreased 
ADC.  FDM has been examined as an early marker of biologic outcome and shows promise 
as a tool to predict treatment efficacy early in the drug development process.12  Although 
much of this work has been performed in analysis of the brain, FDM can be applied in a 
similar fashion as a potential lung disease biomarker.  To use FDM for lung disease, ADC 
images are taken at time points t1 and t2 (t2>t1).  These images are registered together using 
an affine transformation13 using the b = 0 s/cm2 slice to ensure the highest signal image is 
used in the registration.  Unlike in traditional brain FDM, an imaging voxel within the lung 
can be categorized into one of five categories: 1) increased ADC, 2) decreased ADC, 3) no 
change in ADC, 4) lost ventilation (i.e signal void at t2 where there was signal at t1) and 5) 
gained ventilation (i.e signal at t2 where there was a signal void at t1).  In order to determine 
whether a voxel has increased (or decreased) in ADC at t2 versus t1, a threshold (T) must 
be determined to categorize a change as significant.  A voxel is categorized as no change 
in ADC if |ΔADC| < T.  As a first step in determining T, the variability in ADC 
measurements must be determined.  Previous work14 has examined same-day rescan and 
7-day rescan and has demonstrated a coefficient of variation (COV) and mean ADC for 
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never-smokers, mild-moderate COPD and severe COPD.  Using the COV and mean ADC 
for each subgroup, a variability of approximately 0.01 cm2/s applies across all groups.  As 
a preliminary step, I defined a threshold of T = 0.01 cm2/s as a significant deviation from 
the t1 scan. Figure 3-1 shows a sample workflow for analysis of an AATD subject at two 
time points. 
 
Figure 3-1: Functional Diffusion Map Workflow 
A) Two visit ADC maps are co-registered  
B) Functional diffusion map is generated and clustered into 5 distinct non background 
regions 
C) A plot of V1 vs V2 ADC with points above the red line showing regions of increased 
ADC and points below the blue line showing regions of worse ADC.  Green line shows 
line of identity 
In order to evaluate the effect of a landmark based affine transformation and user variability 
on these five distinct regions, a single subject was evaluated five times each day for five 
days.  The coefficient of variation across both same-day and five day variability was 
determined to be 1%, indicating little variation between trials, this is important for 
implementation of this technique.  Future work should be aimed at examining large patient 
databases with multi-visit ADC measurements and evaluating relationships between 
clinical outcomes and FDM measurements.  Although the focus here has been on 2-visit 
ADC maps, it would be possible to extend this to n-visit maps and examine the longitudinal 
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change in ADC either as a voxel-wise slope or possibly through another method of analysis.  
With the focus of this thesis on multiple-b measurements of airspace enlargement, it would 
be simple to extend FDM to Lm maps or any other morphometry measurement acquired 
using the morphomic technique.  
3.4.5 Longitudinal Evaluation of AATD 
This thesis examined AATD disease cross-sectionally.  To build upon this cross-sectional 
evaluation, a longitudinal study evaluating disease progression over longer periods of time 
should be performed to examine the change in lung function as measured by standard 
clinical tools and by using hyperpolarized noble-gas MRI.  A small, preliminary evaluation 
of a single AATD subject (AATD-1 from this thesis) was performed over the course of 
approximately five years (Figure 3-2).   
 
Figure 3-2: Longitudinal Evaluation of AATD 
As shown in Figure 3-2 the subject has lost ventilation over time (primarily in the lower 
lobes as to be expected in AATD related disease) and shows an increase in both ADC and 
RA950 qualitatively located in the basal portion of the lungs.  Although this analysis was 
performed only a single subject it provides motivation for larger longitudinal studies in 
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AATD, with the possibility of examining subjects with and without augmentation therapy.  
In a continuation study currently undergoing in our lab, subjects with AATD are being 
recruited and will be scanned longitudinally (1-3 years follow-up) to examine their lung 
function decline as measured using both spirometry and imaging techniques such as CT 
and hyperpolarized MRI.  Furthermore, by acquiring 129Xe images in this population, the 
techniques used and information gained from this study will be one step closer to clinical 
translation. 
 Significance and Impact 
Alpha-1 antitrypsin deficiency results in early onset chronic obstructive pulmonary disease 
and there is no available cure.  Current therapies rely on slowing disease progression.  
Longitudinal evaluation of this population is done with nonspecific airflow measurements 
and frequent CT scans with the burden of ionizing radiation.  Clinical trial endpoints 
unfortunately still rely on these methods.  Hyperpolarized noble-gas diffusion-weighted 
MRI, in particular Lm, provides an opportunity to fill the role of a clinical trial endpoint 
and provide a measurement of treatment response that is sensitive to both disease 
progression and airspace enlargement.  Diffusion-weighted MRI combines the ability to 
obtain ventilation defect percentage and measurements of tissue microstructure obtainable 
within a single breath-hold without the use of ionizing radiation, making it an attractive 
clinical trial endpoint to gauge treatment efficacy.  Using a smaller sample than currently 
used in clinical trials, treatment efficacy can be evaluated quantitatively using multiple-b 
diffusion MRI and can impact the time and cost associated with development of novel 
treatments for AATD.  
 References 
(1) Hsia, C. C., Hyde, D. M., Ochs, M. & Weibel, E. R. An official research policy 
statement of the American Thoracic Society/European Respiratory Society: 
standards for quantitative assessment of lung structure. American journal of 
respiratory and critical care medicine 2010; 181: 394-418. 
(2) Chapman, K., Bourbeau, J. & Rance, L. The burden of COPD in Canada: results 
from the Confronting COPD survey. Respiratory Medicine 2003; 97: S23-S31. 
 65 
 
(3) Global Alliance against Chronic Respiratory Diseases. World Health Organization 
Fact Sheet N 315, <http://www.who.int/mediacentre/factsheets/fs315/en/> (2012) 
(4) Parra‐Robles, J. et al. The influence of field strength on the apparent diffusion 
coefficient of 3He gas in human lungs. Magnetic resonance in medicine 2012; 67: 
322-325. 
(5) Grebenkov, D. S. Use, misuse, and abuse of apparent diffusion coefficients. 
Concepts in Magnetic Resonance Part A 2010; 36: 24-35. 
(6) Kurz, F. T. et al. Microstructural analysis of peripheral lung tissue through CPMG 
inter-echo time R2 dispersion. PloS one 2015; 10: e0141894. 
(7) Abascal, J. F., Desco, M. & Parra-Robles, J. Incorporation of prior knowledge of 
the signal behavior into the reconstruction to accelerate the acquisition of MR 
diffusion data. arXiv preprint arXiv:1702.02743 2017. 
(8) Chang, Y. V., Quirk, J. D. & Yablonskiy, D. A. In vivo lung morphometry with 
accelerated hyperpolarized (3) He diffusion MRI: a preliminary study. Magn Reson 
Med 2015; 73: 1609-1614. 
(9) Ouriadov, A., Lessard, E., Sheikh, K. & Parraga, G. Pulmonary MRI morphometry 
modeling of airspace enlargement in chronic obstructive pulmonary disease and 
alpha‐1 antitrypsin deficiency. Magnetic Resonance in Medicine 2017. 
(10) Sukstanskii, A. L. & Yablonskiy, D. A. Lung morphometry with hyperpolarized 
129Xe: theoretical background. Magn Reson Med 2012; 67: 856-866. 
(11) Moffat, B. A. et al. Functional diffusion map: a noninvasive MRI biomarker for 
early stratification of clinical brain tumor response. Proceedings of the National 
Academy of Sciences of the United States of America 2005; 102: 5524-5529. 
(12) Moffat, B. A. et al. The functional diffusion map: an imaging biomarker for the 
early prediction of cancer treatment outcome. Neoplasia 2006; 8: 259-267. 
(13) Kirby, M. et al. Hyperpolarized 3He magnetic resonance functional imaging 
semiautomated segmentation. Academic radiology 2012; 19: 141-152. 
(14) Parraga, G. et al. Hyperpolarized 3He ventilation defects and apparent diffusion 
coefficients in chronic obstructive pulmonary disease: preliminary results at 3.0 
Tesla. Invest Radiol 2007; 42: 384-391. 
 
 
 66 
 
4   Appendix 
Appendix A - Permission for Reproduction of Scientific Articles 
 
 
  
 67 
 
Appendix B - Health Science Research Ethics Board Approval Notices 
 
 68 
 
 
  
 69 
 
 
 
  
 70 
 
 
  
 71 
 
 
  
 72 
 
 
  
 73 
 
Appendix C - Curriculum Vitae 
EDUCATION 
2015-   Master of Science in Medical Biophysics (Candidate) 
Department of Medical Biophysics 
The University of Western Ontario, London, Canada 
Supervisor: Dr. Grace Parraga 
 
2015   Bachelor of Science (Honours Physics) 
   Minor in Psychology 
   Department of Physics 
The University of Windsor, Windsor, Canada 
Supervisor: Dr. Roman G. Maev 
POSITIONS 
2015-    Robarts Research Institute 
   London, Ontario 
   Graduate Research Assistant, MSc Candidate 
   Department of Medical Biophysics, The University of Western Ontario 
   Supervisor: Dr. Grace Parraga 
 
2015   Robarts Research Institute 
   London, Ontario 
   Summer Student 
   Supervisor: Dr. Grace Parraga 
 
2013-2015  Institute for Diagnostic Imaging Research 
   Windsor, Ontario 
   Undergraduate Research Assistant 
   Supervisor: Dr. Roman G. Maev 
HONOURS AND AWARDS 
2015 -    Western Graduate Research Scholarship 
   Department of Medical Biophysics, The University of Western Ontario 
Awarded to a full time graduate student for stipend support who has 
maintained an average of 80% or more. 
   Institutional ($1,500 per term) 
 
2016   Educational Stipend Award 
   International Society for Magnetic Resonance in Medicine 
Awarded to support the attendance of students, postdoctoral and clinical 
trainees to present abstracts at the scientific meeting. 
   International ($475 USD) 
 
PUBLICATIONS AND PRESENTATIONS 
A Peer-Reviewed Journal Manuscripts 
Published (2) 
1. A Ouriadov, E Lessard, K Sheikh and G Parraga. Pulmonary MRI Morphometry Modelling of 
Airspace Enlargement in Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin 
Deficiency, Magn Reson Med, doi: 10.1002/mrm.26642 [Epub ahead of print] 
 74 
 
2. G Paulin, A Ouriadov, E Lessard, K Sheikh, DG McCormack and G Parraga. Non-Invasive 
Quantification of Alveolar Morphometry in Elderly Never- and Ex-Smokers Physiol Rep, 3 
(10), 2015, e12583, doi: 10.14814/phy2.12583 
 
Accepted with revisions (1) 
1. E Lessard, HM Young, A Bhalla, D Pike, K Sheikh, DG McCormack, A Ouriadov and G 
Parraga. Pulmonary Magnetic Resonance Imaging Biomarkers of Regional Airspace 
Enlargement in Alpha-1 Antitrypsin Deficiency, Accepted with revisions to Acad Radiol April 
21, 2017 
 
B Proffered Oral Presentations (3) 
1. E Lessard, A Ouriadov, DPI Capaldi, DG McCormack and G Parraga, Novel Biomarkers of 
Lung Parenchyma Destruction and Emphysema Progression in COPD Using Inhaled Gas 
MRI Morphometry. American Thoracic Society Annual Scientific Meeting 2016 San Francisco 
CA May 13-18, 2016 
2. A Ouriadov, E Lessard, DG McCormack and G Parraga, Can the Stretched Exponential 
Model of Gas Diffusion Provide Clinically-Relevant Parenchyma Measurements of Lung 
Disease? International Society of Magnetic Resonance in Medicine Annual Scientific Meeting 
2016 Suntec City, Singapore May 7-13, 2016. 
3. A Ouellette, E Lessard, AM Chertov, RG Maev. Real Time 2D Imaging of the Spot Weld 
Process, The American Society for Non-destructive Testing 23rd Research Symposium, 
March 27, 2014, Las Vegas, NV 
 
C Invited and Proffered Poster Presentations (9) 
1. A Ouriadov, E Lessard, F Guo, HM Young, A Bhalla, DG McCormack and G Parraga. 
Accelerated Diffusion-weighted 129Xe MRI Morphometry of Emphysema. Imaging Network 
of Ontario (ImNO), 15th Annual Imaging Network Ontario Symposium, London, Canada, 
March 15-16, 2016. 
2. A Ouriadov, E Lessard, F Guo, HM Young, A Bhalla, HO Coxson, DG McCormack and G 
Parraga. Biomarkers of Emphysema in COPD and Alpha-1 Antitrypsin Deficiency: 129Xe MRI 
Morphomics. American Thoracic Society Annual Scientific Meeting 2017 Washington DC May 
19-24, 2017. 
3. A Ouriadov, E Lessard, F Guo, HM Young, A Bhalla, DG McCormack and G Parraga. 
Accelerated Diffusion-weighted 129Xe MRI Morphometry of Emphysema in COPD and 
Alpha-1 Antitrypsin Deficiency Patients. International Society of Magnetic Resonance in 
Medicine Annual Scientific Meeting Honolulu, HI April 22-27, 2017. 
4. E Lessard, A Bhalla, A Ouriadov, D Pike, DG McCormack and G Parraga, Longitudinal 
Three-Year Decline in Alpha-1 Antitrypsin Deficiency: Regional Worsening in Emphysema 
and Ventilation. Robarts Research Retreat 2016 London, Canada, June 13, 2016. 
5. E Lessard, A Ouriadov, DG McCormack and G Parraga, Single Compartment model 
estimates of acinar duct measurements form inhaled noble gas MRI: Proof of Concept in 
alpha-1 antitrypsin deficiency emphysema. London Health Research Day 2016 London, 
Canada March 29, 2016. 
6. A Bhalla, A Ouriadov, E Lessard, DG McCormack and G Parraga, Longitudinal MRI 
Morphomics: towards an understanding of response to therapy and disease progression in 
patients with Alpha-1 Antitrypsin Deficiency pulmonary emphysema. London Health 
Research Day 2016 London, Canada March 29, 2016. (Top 100 Poster) 
7. E Lessard, A Ouriadov, DG McCormack and G Parraga, Single Compartment model 
estimates of acinar duct measurements form inhaled noble gas MRI: Proof of Concept in 
alpha-1 antitrypsin deficiency emphysema. International Society of Magnetic Resonance in 
Medicine Annual Scientific Meeting 2016 Suntec City, Singapore May 7-13, 2016. 
8. E Lessard, A Bhalla, A Ouriadov, D Pike, DG McCormack and G Parraga, Longitudinal 
Three-Year Decline in Alpha-1 Antitrypsin Deficiency: Regional Worsening in Emphysema 
and Ventilation. American Thoracic Society Annual Scientific Meeting 2016 San Francisco 
CA May 13-18, 2016. 
 75 
 
9. A Ouriadov, E Lessard, DG McCormack, G Parraga. Single-breath 3He Whole Lung 
Morphometry in Alpha-1 Antitrypsin Deficiency: Towards an Understanding of Parenchymal 
Destruction and Response to Treatment. International Workshop for Pulmonary Functional 
Imaging Edinburgh, UK September 30th, 2015 
 
D Academic Reports 
1. E Lessard, Investigation of Magnetic Field and Current Based Triggers for Use in the 
Ultrasonic Monitoring of the Resistance Spot Weld Process. University of Windsor 
Undergraduate Thesis, Windsor, Ontario, 2014 
 
COMMITEES AND PROFRESSIONAL ACTIVITIES 
2013-2015 University of Windsor 
  Undergraduate Representative 
  Department of Physics 
PROFRESSIONAL SOCIETIES 
2015-2017 American Thoracic Society 
  Student Member 
2015-2017 Canadian Thoracic Society 
  Student Member 
2015-2017 Canadian Organization of Medical Physicists   
  Student Member 
2015-  International Society for Magnetic Resonance in Medicine 
  Student Member 
2014-2016 Canadian Association of Physicists 
  Student Member 
2010-2016 American Physical Society 
  Student Member 
ACADEMIC RESPONSIBILITIES 
Undergraduate Teaching 
2014-2015  Introductory Physics II (University of Windsor: 03-64-141) 
  -Proctored Exams and Laboratory Instructor (2h Lab, 1h Tutorial per week) 
  Introduction to Astronomy II (University of Windsor: 03-64-191) 
  -Proctored Exams and marked group projects. 
  Introductory Physics I (University of Windsor: 03-64-140) 
  -Proctored Exams, marked midterm and final exam. 
 
LEADERSHIP, VOLUNTEER and COMMUNITY ACTIVITIES 
2016-2017 Research Assistant Volunteer, Canadian Alliance for Healthy Hearts & Minds, 
Population Health Research Institute 
Administered Montreal Cognitive Assessments (MoCa) and Digital Substitution 
Exercises. Obtained volunteer physical measurements.  Responsible for using 
DataFax software. 
2015-  Volunteer, London Powerlifting Club, Ontario Powerlifting Association  
2014-2015  Vice President, Physics Club, University of Windsor 
2014  Volunteer, Science Academy, University of Windsor  
2013-2014  Junior Vice President, Physics Club, University of Windsor 
2013  Volunteer, Science Rendezvous, University of Windsor 
